Renin-angiotensin-aldosterone system blockers after KDIGO stage 3 acute kidney injury: use and impact on 2-year mortality in the AKIKI trial

Detalles Bibliográficos
Autores principales: Scarton, Mathilde, Oppenheimer, Anne, Chaïbi, Khalil, Dreyfuss, Didier, Gaudry, Stéphane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6489288/
https://www.ncbi.nlm.nih.gov/pubmed/31036047
http://dx.doi.org/10.1186/s13054-019-2447-0
_version_ 1783414793689890816
author Scarton, Mathilde
Oppenheimer, Anne
Chaïbi, Khalil
Dreyfuss, Didier
Gaudry, Stéphane
author_facet Scarton, Mathilde
Oppenheimer, Anne
Chaïbi, Khalil
Dreyfuss, Didier
Gaudry, Stéphane
author_sort Scarton, Mathilde
collection PubMed
description
format Online
Article
Text
id pubmed-6489288
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-64892882019-05-08 Renin-angiotensin-aldosterone system blockers after KDIGO stage 3 acute kidney injury: use and impact on 2-year mortality in the AKIKI trial Scarton, Mathilde Oppenheimer, Anne Chaïbi, Khalil Dreyfuss, Didier Gaudry, Stéphane Crit Care Letter BioMed Central 2019-04-29 /pmc/articles/PMC6489288/ /pubmed/31036047 http://dx.doi.org/10.1186/s13054-019-2447-0 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Letter
Scarton, Mathilde
Oppenheimer, Anne
Chaïbi, Khalil
Dreyfuss, Didier
Gaudry, Stéphane
Renin-angiotensin-aldosterone system blockers after KDIGO stage 3 acute kidney injury: use and impact on 2-year mortality in the AKIKI trial
title Renin-angiotensin-aldosterone system blockers after KDIGO stage 3 acute kidney injury: use and impact on 2-year mortality in the AKIKI trial
title_full Renin-angiotensin-aldosterone system blockers after KDIGO stage 3 acute kidney injury: use and impact on 2-year mortality in the AKIKI trial
title_fullStr Renin-angiotensin-aldosterone system blockers after KDIGO stage 3 acute kidney injury: use and impact on 2-year mortality in the AKIKI trial
title_full_unstemmed Renin-angiotensin-aldosterone system blockers after KDIGO stage 3 acute kidney injury: use and impact on 2-year mortality in the AKIKI trial
title_short Renin-angiotensin-aldosterone system blockers after KDIGO stage 3 acute kidney injury: use and impact on 2-year mortality in the AKIKI trial
title_sort renin-angiotensin-aldosterone system blockers after kdigo stage 3 acute kidney injury: use and impact on 2-year mortality in the akiki trial
topic Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6489288/
https://www.ncbi.nlm.nih.gov/pubmed/31036047
http://dx.doi.org/10.1186/s13054-019-2447-0
work_keys_str_mv AT scartonmathilde reninangiotensinaldosteronesystemblockersafterkdigostage3acutekidneyinjuryuseandimpacton2yearmortalityintheakikitrial
AT oppenheimeranne reninangiotensinaldosteronesystemblockersafterkdigostage3acutekidneyinjuryuseandimpacton2yearmortalityintheakikitrial
AT chaibikhalil reninangiotensinaldosteronesystemblockersafterkdigostage3acutekidneyinjuryuseandimpacton2yearmortalityintheakikitrial
AT dreyfussdidier reninangiotensinaldosteronesystemblockersafterkdigostage3acutekidneyinjuryuseandimpacton2yearmortalityintheakikitrial
AT gaudrystephane reninangiotensinaldosteronesystemblockersafterkdigostage3acutekidneyinjuryuseandimpacton2yearmortalityintheakikitrial

Ejemplares similares